Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)☆,☆☆
Keywords
Cited by (0)
- ☆
Clinical trial number: NCT00713830. GLP-1 Agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of sulfonylurea (GETGOAL S). Registry: clinicaltrials.gov.
Conflicts of interest statement: JR has served on scientific advisory boards and received honoraria or consulting fees or grants/research support from insulin and GLP-1 receptor agonist manufacturers, Sanofi, Novo Nordisk, Eli Lilly, GlaxoSmithKline, Roche, and Amylin. MH has received speaker honoraria from Roche, Bayer, Lilly, Takeda, GlaxoSmithKline, and Sanofi-Aventis, and advisory board honoraria from Takeda, Bristol-Myers Squibb, Sanofi-Aventis, and GlaxoSmithKline. PS has no competing interests to declare. KWM has received speaker honoraria from Sanofi-Aventis and Takeda. GB, PM, TZ, and IM-B are employees of Sanofi. RER has received research support from Amylin, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis, and Takeda, and has acted as a consultant for Amylin, Eli Lilly, Novo Nordisk, Roche, Sanofi-Aventis, and Takeda.
- ☆☆
Previous presentations: These data were presented in part as posters at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting, Lisbon, Portugal, 12–16 September 2011, and the World Diabetes Congress of the International Diabetes Federation (IDF), Dubai, UAE, 4–8 September 2011.